Arup Laboratories
Arup Laboratories is recorded as a service provider in 93 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 93 trials · Latest update first
Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double-blind, Placebo-controlled Study with a Long-term Open-label Extension
Sponsor Janssen - Cilag International
- Start (EU)
- Latest update
- Estimated end
CONQUEST Platform Clinical Study for Conquering Scleroderma: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2b Platform Clinical Study to Evaluate the Safety and Efficacy of Investigational Products in Participants with Interstitial Lung Disease Secondary to Systemic Sclerosis
Sponsor Scleroderma Research Foundation
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Open-Label, Multicenter Clinical Study of The Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Profiles of CGT9486 as a Single Agent in Patients with Advanced Systemic Mastocytosis
Sponsor Cogent Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
C6491013 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Once-Monthly PF-08653944 in Adults with Overweight or Obesity (VESPER 6)
Sponsor Pfizer Inc.
- Start (EU)
- Latest update
- Estimated end
A Global, Phase 3, Multicenter, Open-Label Study to Assess the Long-Term Safety and Tolerability of NBI-1117568 in Adults with Schizophrenia
Sponsor Neurocrine Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
ZENITH: A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
Sponsor Alnylam Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-blind, Study to Demonstrate Pharmacokinetic Similarity, and Evaluate Safety, Immunogenicity, Pharmacodynamics and Clinical Effects between ABP 692 and Ocrevus® (Ocrelizumab) in Subjects with Relapsing-remitting Multiple Sclerosis
Sponsor Amgen Inc.
- Start (EU)
- Latest update
- Estimated end
A Global, Randomized, Open-label, Multicenter Phase 3 Trial Evaluating BJT-778 vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)
Sponsor Mirum Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Dose Comparison and Exploratory Efficacy Study of Orally Administered SAT-3247 in Ambulatory DMD Patients
Sponsor Satellos Bioscience Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Efficacy and Safety Study of HBS-301 in Participants with Idiopathic Hypersomnia (IH) Followed by an Open-label Extension
Sponsor Harmony Biosciences Management Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
An Open-Label, Long Term Safety and Efficacy Study of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE).
Sponsor Ionis Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Efficacy and Safety Study of HBS-301 in Participants with Narcolepsy Followed by an Open-label Extension
Sponsor Harmony Biosciences Management Inc.
- Start (EU)
- Latest update
- Estimated end
A Global Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of mRNA-3705 in Participants with Isolated Methylmalonic Acidemia Due to Methylmalonyl-CoA Mutase Deficiency
Sponsor Moderna Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Patients With Graves' Disease
Sponsor Immunovant Sciences GmbH
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Proof of Concept (POC) Study Evaluating the Safety, Tolerability, and Efficacy of Nintedanib Solution for Inhalation (AP02) in Participants with Idiopathic Pulmonary Fibrosis (IPF) (AURA-IPF)
Sponsor Avalyn Pharma Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Randomized, Double-blind, Placebo-controlled Global Study of Sapablursen in Polycythemia Vera
Sponsor Deciphera Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
HMBeacon: A Phase 2, Randomized, Double-blind Study of the Safety, Tolerability, Efficacy, and Pharmacodynamics of Multiple Dose ALN-6400 in Female Patients with Von Willebrand Disease (VWD) and Heavy Menstrual Bleeding (HMB)
Sponsor Alnylam Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety, Tolerability, and Efficacy of MZE782 in Adults with Phenylketonuria (PKU)
Sponsor Maze Therapeutics Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Global, Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1117568 in Adults with Schizophrenia Who Warrant Inpatient Hospitalization
Sponsor Neurocrine Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
J4G-MC-JZVD - FORAGER-2: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined with Enfortumab Vedotin and Pembrolizumab in Adults with Untreated Locally Advanced or Metastatic Urothelial Carcinoma with an FGFR3 Genetic Alteration.
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Arup Laboratories?
The 2026-10-09 snapshot links Arup Laboratories to 93 distinct CTIS trials. Recorded services include Laboratory services, Genetic testing, Genetic Testing, Genotyping, among 43 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Arup Laboratories?
The most frequently recorded therapeutic areas are Immunology, Neurology, Genetic and Congenital Disorders, Metabolic Disorders. Recorded phases include Phase 2, Phase 3, Phase 1, Phase 4. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Arup Laboratories conducted?
The linked trials record locations in 25 countries, including Spain, Italy, Germany, France, Poland. These are trial locations, not confirmed office locations or countries where Arup Laboratories delivered services.
What can this page tell me about Arup Laboratories's trial experience?
Browse 93 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 2 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Arup Laboratories. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Arup Laboratories Inc.